{"id":2918,"date":"2016-11-16T18:14:53","date_gmt":"2016-11-16T18:14:53","guid":{"rendered":"http:\/\/www.medicalmarijuanainc.com\/?p=18383"},"modified":"2016-11-16T18:14:53","modified_gmt":"2016-11-16T18:14:53","slug":"u-s-patent-allowance-granted-medical-marijuana-inc-s-investment-aximr-biotech-use-cannabinoids-controlled-release-chewing-gum","status":"publish","type":"post","link":"https:\/\/medicalmarijuanainc.com\/2016\/11\/16\/u-s-patent-allowance-granted-medical-marijuana-inc-s-investment-aximr-biotech-use-cannabinoids-controlled-release-chewing-gum\/","title":{"rendered":"U.S. Patent Allowance Granted to Medical Marijuana, Inc.’s Investment AXIM(R) Biotech for Use of All Cannabinoids in Its Controlled Release Chewing Gum"},"content":{"rendered":"

SAN DIEGO, CA–(Marketwired – November 16, 2016) – <\/span>Medical Marijuana, Inc.<\/span> (OTC PINK: MJNA) announced today that its major investment <\/span>AXIM\u00ae Biotechnologies, Inc. (AXIM\u00ae Biotech<\/span><\/a>) (<\/span>AXIM<\/span><\/a>), a world leader in hemp cannabinoid research and development, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number <\/span>9,433,601<\/span><\/a>, a patent that claims the use of all cannabinoids in cannabinoid-containing controlled-release chewing gum products. A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from the application, filed in April 2015. This patent covers the inclusion of all cannabinoids (both natural and synthetic) in a chewing gum delivery system, including Tetrahydrocannabinol (THC), all of which may be incorporated in the Company’s chewing gum products.<\/span><\/p>\n

This new patent is an extension of AXIM\u00ae Biotech’s patent for chewing gum as delivery methods for cannabidiol (Chewing Gum Compositions Comprising Cannabinoids). Prior to this new allowance, Patent <\/span>9,023,322<\/span><\/a> only claimed gum products as a delivery mechanism for cannabidiol (CBD), a well-known cannabinoid.<\/span><\/p>\n

“We congratulate the AXIM team on receiving this new patent, another major milestone in the Company’s continued efforts to research new solutions using cannabinoid-based drugs,” said Dr. Stuart Titus, CEO of Medical Marijuana, Inc.<\/span><\/p>\n

“This patent will enable AXIM to include any of the at least 85 different cannabinoid compounds found in the cannabis plant, including CBD and THC, into its multiple cannabinoid controlled-release chewing gum products,” added Dr. Titus. “As investors in AXIM, we are enthusiastic about how the Company continues to move forward as a leader in cannabinoid research and development.”<\/span><\/p>\n

AXIM\u00ae Biotech developed the patents it now owns for chewing gum as a delivery method for cannabinoids into two separate products. Its CBD-only <\/span>Canchew\u00ae gum<\/span><\/a> is marketed and is legal to purchase wherever CBD hemp oil products are sold. <\/span>AXIM\u00ae Biotech<\/span><\/a> holds the exclusive rights to market and distribute CanChew\u00ae Gum globally. <\/span>CanChew<\/span><\/a>\u00ae is a botanical hemp-derived CBD chewing gum with a unique oral mucosal absorbance delivery system. Features listed on the <\/span>CanChew<\/span><\/a>\u00ae website include:<\/span><\/p>\n